Wave Life Sciences Q2 FY26 net loss widens to $69.36 million; revenue drops 73.88% to $2.27 million

Reuters2026/07/30 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Wave Life Sciences posted a net loss of USD 69.36 million, widening from USD 50.47 million a year earlier.
Revenue fell 73.88% to USD 2.27 million, while R&D expenses rose 18% to USD 51.29 million.
G&A costs climbed 37.74% to USD 24.78 million; cash, cash equivalents and marketable securities totaled USD 490.6 million.
Dosing began in the Phase 2a multidose INLIGHT trial of obesity drug WVE-007; Phase 2 combo and post-incretin maintenance trials targeted for 2H 2026.
FDA meeting set for end of summer 2026 on a potential accelerated approval pathway for AATD candidate WVE-006; WVE-008 CTA filing still planned for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300730PRIMZONEFULLFEED9800628) on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Wave Life Sciences Q2 FY26 net loss widens to $69.36 million; revenue drops 73.88% to $2.27 million

You may also like

Crypto prices